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Abstract
Background: The impact of HIV drug resistance mutations in salvage therapy has been widely
investigated in adults. By contrast, data available of predictive value of resistance mutations in
pediatric population is scarce.
Methods:  A multicenter, retrospective, observational study was conducted in children who
received rescue salvage antiretroviral therapy after virologic failure. CD4 counts and viral load
were determined at baseline and 6 months after rescue intervention. Genotypic HIV-1 resistance
test and virtual phenotype were assessed at baseline.
Results: A total of 33 children met the inclusion criteria and were included in the analysis. The
median viral load (VL) and median percentage of CD4+ at baseline was 4.0 HIV-RNA log copies/ml
and 23.0% respectively. The median duration that children were taking the new rescue regimen was
24.3 weeks (23.8–30.6). Overall, 47% of the 33 children achieved virological response at 24 weeks.
When we compared the group of children who achieved virological response with those who did
not, we found out that mean number of PI related mutations among the group of responders was
3.8 vs. 5.4 (p = 0.115). Moreover, the mean number of susceptible drugs according to virtual
phenotype clinical cut-off for maximal virologic response was 1.7 vs. 0.8 and mean number of
susceptible drugs according to virtual phenotype cut-off for minimal virlologic response was 2.7 vs.
1.3 (p < 0.01 in all cases). Eighteen children were rescued with a regimen containing a boosted-PI
and virological response was significantly higher in those subjects compared with the others (61.1%
vs. 28.6%, p < 0.01).
Conclusion: Salvage treatment containing ritonavir boosted-PIs in children with virological failure
was very efficient. The use of new tools as virtual phenotype could help to improve virologic
success in pediatric population.
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Background
Treatment with highly active antiretroviral therapy
(HAART) has resulted in great reductions in mortality and
progression of HIV-1 disease in both adults and children.
Increasingly, these children are surviving through to ado-
lescent into adult life [1]. However, children taking
antiretroviral therapy tend to present with higher plasma
viral load (VL) and lower virologic response rates than
adults. Whenever viral replication is inefficiently control-
led, virologic failure happens more quickly, allowing the
selection of HIV-1 quasispecies resistant to antiretroviral
drugs [2,3].
Guidelines for antiretroviral treatment (ART) in children
recommend an early and active approach, which usually
includes one Protease Inhibitor (PI) or Non-Nucleoside
Analogue Reverse Transcriptase Inhibitor (NNRTI) and
two Nucleosides Analogue Reverse Transcriptase Inhibi-
tors (NRTI) [4]. Although it includes the same antiretrovi-
ral drugs as in adults, ART in children has special features
like: unsuitable formulations with inadequate pharma-
cokinetics and poor palatability and lack of compliance
which is usually one of the main causes of lower response
rates in children [5,6].
The use of co formulation of PIs with a fixed dose of riton-
avir (rit) has shown a greater activity in both antiretrovi-
ral-naïve and treatment experienced HIV-1 infected
children than previous PIs because of its pharmacokinetic
advantages due to low-dose of rit which enhance the
antiretroviral activity of the other PI. [7-9]. However, the
extended use of PIs as salvage therapy for heavily pre-
treated subjects has not fulfilled its expectations [10-12].
Moreover, there are few studies available concerning pre-
dictive factors of virological success when PIs/rit are used
in a second or third-line of HAART in this special popula-
tion [7,13].
The aim of this retrospective study was to analyze and
determine predictive factors of virological success when
PIs are used as a salvage therapy for HIV-1 infected chil-
dren.
Methods
Population and study design
A multicenter retrospective, observational study was con-
ducted to evaluate the predictive factors of virological
responses when PI-containing regimens were used as sal-
vage therapy in vertically HIV-1 infected children. Patients
were recruited from three large Spanish Hospitals (Hospi-
tal Universitario Doce de Octubre, Hospital Infantil La
Paz and Hospital Carlos III), with a specialized HIV/AIDS
unit in pediatrics. The inclusion criteria were: (1) older
than one year of age, (2) been previously treated with
antiretroviral therapy including PIs, (3) at least 6 months
of follow-up with a salvage regimen and (4) having a
resistance test (genotypic and phenotypic) at baseline.
Viral load and CD4 cell count measurements
Plasma viremia was determined using the bDNA assay
version 3.0 (Bayer, Barcelona, Spain), which has a lower
detection limit of 50 HIV-RNA copies/ml. A Virological
Response (VR) was considered as significant when plasma
HIV-RNA reductions were greater than 1 log and/or went
to less than 50 HIV-RNA copies/ml. The CD4+ lym-
phocyte count was measured by flow cytometry (Coulter,
Madrid, Spain). Patients were monitored every three
months. Clinical examination and laboratory tests were
performed at each visit. There was not a uniform approach
regarding antirretroviral drugs included in the salvage reg-
imen. Instead, each paediatrician administered the appro-
priate ART regimen and changed the drugs according to
his/her interpretation of the children data. The adherence
of antiretroviral drugs included in the salvage regimen,
was measured by each paediatrician by pill count and
through interviews with their parents or tutors.
Resistance analysis
Genetic sequences of both HIV protease (PRO) and retro-
transcriptase (RT) genes were obtained at baseline using
and automatic sequencer (ABI Prism 3100, Applied Bio-
systems, Foster City, CA). Interpretation of drug resistance
mutations was performed following the latest IAS-USA
guidelines [9].
Virtual phenotype
Genetic sequences obtained at baseline were sent to Virco
for the estimation of the virtual phenotype (vPT). vPT is a
probabilistic estimate of the phenotype (fold-changes in
IC50) for a patient's HIV genotype by matching it with
other genotypes available in large databases in which they
are paired with phenotypes. The phenotypes matching
distinct genotypes close to the one tested are used to pro-
duce an average phenotype for each drug. This strategy
may allow the use of phenotypic information avoiding
the difficulties and cost of real phenotypes. Results of the
analysis were expressed for each drug as Clinical cut-off
values (CCO) which are based on virologic response
observation (change in VL) in treated patients, and give an
indication of how response is affected by viral resistance.
CCO provide a higher degree of correlation with virologic
outcome. The lower clinical cut-off (CCO1) is the base-
line Fold Change associated with 20% loss of the wild
type virologic response due to viral resistance. The upper
clinical cut-off (CCO2) is the baseline Fold Change with
an 80% loss of the wild type virologic response due to
viral resistance. CCO1 and CCO2 were considered for
each drug according to the latest values described by
Virco.
Statistical analyses
Continuous and categorical data were expressed as
median [interquartile ranges (IQR)] and percentages
respectively. Univariate analysis was performed to com-
pare baseline characteristics following virologicalBMC Infectious Diseases 2007, 7:55 http://www.biomedcentral.com/1471-2334/7/55
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response. Categorical and continuous variables, were
compared with the chi-square test (Yates and Fisher cor-
rection when necessary) and non-parametric tests (Mann-
Whitney U), respectively. Univariate and multivariate
binary logistic regression analyses were used to identify
baseline characteristics associated with VR. All statistical
analyses were conducted using the SPSS package (v11.0;
Chicago, IL, USA), and all differences were considered to
be significant when p values were below 0.05.
Results
A total of 33 children were included in the study. Distri-
bution according to sex was; 17 boys (51.5%) and 16 girls
(48.5%). Baseline characteristics of the study population
are recorded in Table 1. The median age at baseline was
11.7 (7.5–14.2). Median time of previous exposure to
antiretroviral drugs among the whole group of patients
was 83 months (49–119) and by drug families was 84
months (49–119) for NRTIs, 5 months (0.0–31) for
NNRTIs and 61 months (38–73) for PIs.
All children had been exposed to at least one PI before the
first determination. The proportion of children who have
been treated with different PI were as follows: Nelfinavir
(NFV) (78.8%), Lopinavir/ritonavir (LPV/rit) (36.4%),
Ritonavir (RTV) (30.3%), Indinavir (IDV) (21.2%),
Saquinavir (SQV) (21.2%) and Amprenavir (APV)
(6.1%). The number of PI that the children have taken
before the baseline determination was: 48.6% had taken
1, 24.2% had taken 2, 15.1% had taken 3, 9.1% had taken
4 and 3% had taken 5. At baseline all the children take a
PI as part of the salvage regimen. At time of the analysis,
60.6% were using NFV, 30.3% LPV/rit, 6.1% IDV and
3.0% SQV/rit.
The median CD4+ cell counts and percentage at baseline
were 707.0 (537.5–941) and 23.0 % (19.5–32), and the
CD8+ cell counts was 1309.0 (967.2–1996.5) and 45.0%
(33.5–57.5). Median baseline viral load was 4.0 (3.4–4.6)
HIV-RNA log copies/ml. At baseline, the median number
of Nucleotide Analogue Mutations (NAMs) was 3.0 (1.5–
4) and the median number of protease resistance muta-
tions was 5.0 (2–6.5). M184V was found in 11 children
(33%); 3 of them (30.3%) were resistant to Abacavir and
1 of them (15.2%) was resistant to Tenofovir according to
the virtual phenotype. At baseline, 42.4% of children have
NNRTI mutations; 30.3% have the K103N and 15.2% the
Y181C.
Virological response defined as plasma HIV-RNA reduc-
tions greater than 1 log and/or VL less than 50 HIV-RNA
copies/ml was achieved in 46.9% of children in the first
24 weeks of follow-up. However, 66.6% of them reached
undetectable viremia after 24 weeks of follow-up. When
we analyze the decrease in VL among patients who
achieved virologic response and those who did not, we
found the following differences: the former group had a
mean decrease of log VL of -1.8 vs. -0.2 (p = 0.01). Further-
more, when we compared the variation of the percentage
of CD4+ and CD8+ cell counts between the two groups,
virological responders had a mean increase in the %CD4+
cell count of 5.3 vs. 0.6 (p = 0.14) and a mean decrease of
%CD8+ cell count of -4.7 vs. 0.6 (p = 0.01). Finally, when
we compared the group of children who achieved virolog-
ical response with those who did not, we found the fol-
lowing differences: mean number of PI related mutations
was 3.8 vs. 5.4 (p = 0.11), mean number of susceptible
drugs according to cut-off for maximal virologic response
(CCO1) 1.7 vs. 0.8 (p = 0.03) and mean number of sus-
ceptible drugs according to cut-off for minimal virlologic
response (CCO2) 2.7 vs. 1.3 (p = 0.01), respectively.
PI combinations with low doses of ritonavir were used in
18 children; 15 received LPV/rit, 2 Fosamprenavir/rit and
1 SQV/rit. None of them received a double boosting of
PIs. Virological response was significantly higher in those
subjects rescued with boosting PIs combinations com-
pared with the others (61.1% vs. 28.6%, p = 0.09).
In the univariate analyses, there was no association
between the number of baseline protease resistance muta-
tions and virological response. Moreover, there was also
not association between virological success and RT resist-
ance mutations, the previous length of antiretroviral ther-
apy, previous length of PI exposure, number of PI
previously received or rescue interventions with boosted-
PI. Nevertheless, we found association between the
number of drugs considered as susceptible according to
CCO1 and CCO2 and the use of an active PI in salvage
regimens (Table 2). In the multivariate analysis, a lower
Table 1: Baseline characteristics of the study population.
N3 3
Sex (%)
Male 51.5
Median Age (years) 11.7 (7.5–14.2)
Median % of Baseline CD4 counts 23.0 (19.5–32.0)
Median % of Baseline CD8 counts (%) 45.0 (33.5–57.5)
Median Baseline VL (HIV-RNA Log copies/ml) 4.0 (3.4–4.6)
Length of ARV therapy (months) 83.0 (49.0–119.0)
Length of PI exposure (months) 61.0 (38.0–73.0)
Length of NRTI exposure (months) 84.0 (49.0–119.0)
Length of NNRTI exposure (months) 5.0 (0.0–31.0)
Median number of previous PI exposure 2.0 (1–3.0)
Median number of NAMs 3.0 (1.5–4.0)
Median number of protease resistance mutations 5.0 (2.0–6.5)
Results are expressed as median (IQR) (VL: viral load; ARV: 
antirretroviral treatment; PI: protease inhibitors; NAMs; nucleotide 
analogue mutations: M41L, D67N, K70R, L210W, T215Y/F y K219Q/
E/R/S/N)BMC Infectious Diseases 2007, 7:55 http://www.biomedcentral.com/1471-2334/7/55
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number of PI previously received and a higher number of
drugs considered as susceptible according to CCO2 were
independently associated with virological response (Table
2).
Discussion
In this study, we evaluate the predictive factors of success
when PIs are used as salvage therapy in a group of heavily
pretreated HIV-infected children with virological failure.
We found that nearly half of them achieve virological
response after rescue interventions. Our result are similar
to other studies which also have been carried among chil-
dren in real life situations [8,12].
Several factors were associated with virological response
and could help to predict success. The numbers of drugs
susceptible defined by the clinical cut-off of the virtual
phenotype, as well as the use of an active PI in the rescue
intervention were significantly associated with virological
response in the univariate analyses. Moreover, rescue
intervention based in boosting-PI combination, a lower
number of baseline protease resistance mutations and a
lower number of previous PI exposure were also associ-
ated with virological response although it not reach statis-
tical significance. It was probably due to the small size of
the study population. These factors appear to be signifi-
cantly associated with virological response in rescue inter-
vention in studies conducted in adult population [7,10].
The presence of 5 more protease resistance mutations as
well as the use of boosting-PI combinations has been
associated with significant virological response in adults
who initiated rescue intervention based on boosting-PI
combinations. However, children usually have lower viro-
logic response rates than adults due partially to lower
treatment adherence leading to underestimation in the
factors associated with virological response. Besides, the
fact that viral loads are higher among children than in
adults, can lead to the development of resistance muta-
tions which could reduce the effectiveness of antiretroviral
drugs in further combinations.
Our study has several limitations primarily due to the
small sample size. We did not asses the relevance of other
classes of antiretroviral drugs in the rescue regimen
because HAART combinations were not homogeneous in
the population as it is a retrospective study based in a real
life situation. In addition, some variables identified as
predictive factors, like number of active PIs in salvage reg-
imen and number of drugs considered as susceptible
according to virtual phenotype might not be independent.
Moreover, we did not measure other factors such as phar-
macokinetic or drug interactions which might have had
influence in the virological success of our population.
Besides, global adherence in our cohort was around 90%
(data not shown) but it was not identify as a prognostic
factor due to the short period of follow-up included in our
study.
In the multivariate analyses only the number of drugs
used according with the CCO2 and a lower number of
previous PI received were independently associated with
virological response. Clinical cut-offs are based on viro-
logical response observations in treated patients giving an
indication of how the response is affected by viral resist-
ance [3,14]. This approaching provide a higher degree of
correlation with virologic response in a given patient
[7,15-18]. CCO2 shows the 80% loss of the wild type viro-
logic response due to resistance. That means resistance
patterns that compromise partially the effectiveness of the
drug. In our study, the inclusion of drugs considered as
partially susceptible measured by the CCO2 provided a
favourable virologic response. In children with multiple
exposures to different antiretrovirals and who have devel-
oped complex resistance patterns, the identification of
drugs partially active is useful for the design of rescue
intervention in this population. However, more studies
with higher sample sizes which evaluate the usefulness of
new tools like virtual phenotypic resistance test or the
combination of pharmacokinetics parameters and resist-
ance test are needed to improve the management of HIV-
infected children.
Table 2: Factors associated with virological response (univariate and multivariate analyses).
Univariate analysis Multivariate analysis
OR (95% CI) p OR (95% CI)
Rescue with PI/rit 3.93 (0.88 to 17.56) 0.07 7.57 (0.58 to 99.31) 0.12
Previous length of ARV exposure 0.99 (0.97 to 1.01) 0.29 - -
Previous length of PI exposure 0.98 (0.94 to 1.01) 0.19 - -
No. previous PIs exposure 0.61 (0.29 to 1.25) 0.18 0.23 (0.06 to 0.89) 0.03
No. susceptible drugs according to CCO1 2.16 (1.02 to 4.57) 0.04 0.22 (0.03 to 1.57) 0.13
No. susceptible drugs according to CCO2 4.99 (1.55 to 16.05) 0.01 5.34 (1.23 to 23.11) 0.02
No. active PIs in the salvage regimen according to virtual phenotype 6.60 (1.40 to 31.05) 0.02 0.64 (0.03 to 11.58) 0.76
No. NAMs 0.85 (0.54 to 1.32) 0.46 - -
No. protease resistance mutations 0.81 (0.62 to 1.06) 0.12 0.89 (0.56 to 1.46) 0.65
(OR: Odds ratio; PI: protease inhibitor; RIT: ritonavir; ARV: antiretroviral treatment; CC01: lower clinical cut-off; CC02: upper clinical cut-off; 
NAMs: nucleotide analogue mutations: M41L, D67N, K70R, L210W, T215Y/F y K219Q/E/R/S/N)BMC Infectious Diseases 2007, 7:55 http://www.biomedcentral.com/1471-2334/7/55
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Conclusion
In conclusion, our results showed higher rates of virolog-
ical success when boosted-PIs are included in salvage regi-
mens. New strategies as virtual phenotype could improve
virological responses and could contribute to select the
most appropriate regimen in treatment experienced chil-
dren, when antiretroviral drugs are not so available.
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